Safety and efficacy of oral slow release morphine for maintenance treatment in heroin addicts: A 6-month open noncomparative study

European Addiction Research

Volumn 12, Issue 2, 2006, Pages 53-60

  Vasilev, Georgi N ^a,b   Alexieva, Daniela Z ^a   Pavlova, Rositsa Z ^a  

^a Ministry of Health Sofia   (Bulgaria)

^b National Program for Control and Prevention of HIV/AIDS ^*  (Bulgaria)

Author keywords

Heroin dependency; Maintenance treatment; Slow release morphine

Indexed keywords

DIAMORPHINE; DIAZEPAM; LAXATIVE; MORPHINE; OPIATE; SUBSTITOL; ZOLPIDEM;

ADULT; ANXIETY DISORDER; ARTICLE; BULGARIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DROWSINESS; DRUG CAPSULE; DRUG DETOXIFICATION; DRUG EFFICACY; DRUG FATALITY; DRUG RELEASE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DYSPHORIA; FEMALE; HEROIN DEPENDENCE; HOPELESSNESS; HUMAN; HYPERSOMNIA; INSOMNIA; MAINTENANCE THERAPY; MALE; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; SINGLE BLIND PROCEDURE; SLOW RELEASE FORMULATION; SOCIAL DISABILITY; STATISTICAL SIGNIFICANCE; SUBSTITUTION THERAPY; SUICIDAL BEHAVIOR; SWEATING; TITRIMETRY; TREATMENT WITHDRAWAL; VALIDATION PROCESS; VITAL SIGN; WELLBEING; WITHDRAWAL SYNDROME;

ADULT; BULGARIA; CAPSULES; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HEROIN; HEROIN DEPENDENCE; HUMANS; MALE; MIDDLE AGED; MORPHINE; QUALITY OF LIFE; SUBSTANCE ABUSE, INTRAVENOUS; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT OUTCOME;

EID: 33645004157     PISSN: 10226877     EISSN: None     Source Type: Journal    
DOI: 10.1159/000090423     Document Type: Article

References (33)

1. Office of National Drug Control Policy: National Drug Control Strategy: 2000 Annual Report. Washington, Government Printing Office, 2000.
2. European Monitoring Centre for Drugs and Drug Addiction: Annual report 2004: the state of the drugs problem in the European Union and Norway. Luxembourg, Office for Official Publications of the European Communities, 2004, pp. 50-61.
3. National anti-drug strategy of the Republic of Bulgaria 2003-2008, www.mvr.bg (English) > Legal Framework > National Strategies > (pdf).
4. Guichard A, Lert F, Calderon C, Gaigi H, Maguet O, Soletti J, Brodeur JM, Richerd L, Benigrini M, Zunzunegui MV: Illicit drug use and injection practice among drug users on methadone and buprenorphine maintenance treatment in France. Addiction 2003;98:1585-1597.
5. Ward J, Mattick R, Hall W: The effectiveness of methadone maintenance treatment: an overview. Drug Alcohol Rev 1994;13:327-336.
6. Gossop M, Marsden J, Stewart D, Kidd T: The National Treatment Outcome Research Study (NTORS): 4-5 year follow-up results. Addiction 2003;98:291-303.
7. Lavignasse P, Lowenstein W, Batel P, Constant MV, Jourdain JJ, Kopp P, Reynaud-Maurupt C, Riff B, Videau B, Mucchielli A: Economic and social effects of high-dose buprenorphine substitution therapy: six-month results. Ann Med Interne (Paris) 2002; 153(suppl 3):S20-S26.
8. United Nations Office for Drug Control and Crime Prevention: World Drug Report 2000. New York, Oxford University Press, 2000.
9. European Monitoring Centre for Drugs and Drug Addiction: Annual report 2004: The State of the Drugs Problem in the European Union and Norway. Luxembourg, Office for Official Publications of the European Communities, 2004, pp. 50-61.
10. Mitchell TB, White JM, Somogyi AA, Bochner F: Comparative pharmacodynamics and pharmacokinetics of methadone and slow-release oral morphine for maintenance treatment of opioid dependence. Drug Alcohol Depend 2003;72:85-94.
11. Dyer KR, White JM: Patterns of symptom complaints in methadone maintenance patients. Addiction 1997;92:1445-1455.
12. Bell J, Zador D: A risk benefit analysis of methadone maintenance treatment. Drug Safety 2000;22:179-190.
13. Déglon J-J, Martin J-L, Imer RL: Methadone patients' sexual dysfunctions: clinical and treatment issues. Heroin Add Rel Clin Probl 2004;6:17-26.
14. Johnson EJ: Buprenorphine: how to use it right. Drug Alcohol Depend 2003;70:59-77.
15. Pernerger TV, Giner F, del Rio M, Mino A: Randomized trial of heroin maintenance programme for addicts who fail in conventional drug treatments. BMJ 1998;317:13-18.
16. van den Brink W, Hendriks VM, Blanken P, Koeter MWJ, van Zwieten BJ, van Ree JM: Medical Prescription of heroin to treatment resistant heroin addicts: two randomized controlled trials. BMJ 2003;327:310.
17. Hagen NA, Thirlwell M, Eisenhoffer J, Quigley P, Harsanyi Z, Drake A: Efficacy, safety, and steady-state pharmacokinetics of once-a-day controlled-release morphine (MS Contin XL™) in cancer pain. J Pain Symptom Manage 2005; 29:80-90.
18. Fischer G, Presslich O, Diamant K, Schneider C, Pezawas L, Kasper S: Oral morphine-sulphate in the treatment of opiate dependent patients. Alcoholism 1996;32:35-43.
19. Kraigher D, Ortner R, Eder H, Schindler S, Fischer G: Slow-release morphine hydrochloride for maintenance therapy of opioid dependence. Wien Klin Wochenschr 2002;114:904-910.
20. Fischer G, Jagsch R, Eder H, et al: Comparison of methadone and slow-release morphine maintenance in pregnant addicts. Addiction 1999;94:231-239.
21. Eder H, Jagsch R, Kraigher D, Primorac A, Ebner N, Fischer G: Comparative study of the effectiveness of slow-release morphine and methadone for opioid maintenance therapy. Addiction 2005;100:1101-1109.
22. The International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM): Washington, National Center for Health Statistics, US Department of Health & Human Services. www.cdc.gov/nchs.
23. McLellan AT, Luborsky L, Woody GE, O'Brien CP: An improved diagnostic evaluation instrument for substance abuse patients. The Addiction Severity Index. J Nerv Ment Dis 1980;168:26-33.
24. Hamilton M: Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278-296.
25. Gossop M: The Development of a Short Opiate Withdrawal Scale (SOWS). Addict Behav 1990;15:487-490.
26. Zung WWK: A self-rating depression scale. Arch Gen Psychiatry 1965;12:63-70.
27. Goldberg DP, Hillier VF: A scaled version of the General Health Questionnaire. Psychol Med 1979;9:139-145.
28. Beck AT, Weissmann A: The measurement of pessimism: the hopelessness scale. J Consult Clin Psychol 1974;42:861-865.
29. Ivanov Vl (ed): Klinichna psihologija. Sofia, Medicina i fizkultura, 1976, pp 170-171.
30. Pacini M, Mellini A, Attilia ML, Ceccanti M, Maremmani I: Alcohol abuse in heroin addicts: An unfolding metabolic destiny. Heroin Add Rel Clin Probl 2005;7:31-38.
31. Zisook S, McAdams LA, Kuck J, Harris MJ, Bailey A, Patterson TL, Judd LL, Jeste DV: Depressive symptoms in schizophrenia. Am J Psychiatry 1999;156:1736-1743.
32. Thompson LW, Futterman A, Gallagher D: Assessment of late-life depression. Psychopharmacol Bull 1988;24:577-586.
33. Mitchell TB, White JM, Somogyi AA, Bochner F: Slow-release oral morphine versus methadone: a crossover comparison of patient outcomes and acceptability as maintenance pharmacotherapies for opioid dependence. Addiction 2004;99:940-945.